127 related articles for article (PubMed ID: 29893861)
1. Mucositis with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of randomized controlled trials.
Li J; Xie J
Jpn J Clin Oncol; 2018 Aug; 48(8):718-727. PubMed ID: 29893861
[TBL] [Abstract][Full Text] [Related]
2. Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: A meta-analysis of 18 randomized controlled clinical trials.
Miroddi M; Sterrantino C; Simonelli I; Ciminata G; Phillips RS; Calapai G
Crit Rev Oncol Hematol; 2015 Nov; 96(2):355-71. PubMed ID: 26160607
[TBL] [Abstract][Full Text] [Related]
3. Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis.
Qi WX; Fu S; Zhang Q; Guo XM
BMC Med; 2014 Nov; 12():203. PubMed ID: 25369798
[TBL] [Abstract][Full Text] [Related]
4. Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials.
Li J; Yan H
Cancer Chemother Pharmacol; 2018 Oct; 82(4):571-583. PubMed ID: 30006755
[TBL] [Abstract][Full Text] [Related]
5. Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial.
Zhu J; Zhao W; Liang D; Li G; Qiu K; Wu J; Li J
Int J Clin Oncol; 2018 Apr; 23(2):389-399. PubMed ID: 29181651
[TBL] [Abstract][Full Text] [Related]
6. Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials.
Wang Q; Qi Y; Zhang D; Gong C; Yao A; Xiao Y; Yang J; Zhou F; Zhou Y
Tumour Biol; 2015 May; 36(5):3471-82. PubMed ID: 25542231
[TBL] [Abstract][Full Text] [Related]
7. Systematic review and meta-analysis of the risk of severe and life-threatening thromboembolism in cancer patients receiving anti-EGFR monoclonal antibodies (cetuximab or panitumumab).
Miroddi M; Sterrantino C; Simmonds M; Caridi L; Calapai G; Phillips RS; Stewart LA
Int J Cancer; 2016 Nov; 139(10):2370-80. PubMed ID: 27450994
[TBL] [Abstract][Full Text] [Related]
8. Fatigue with epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients: A meta-analysis of randomized controlled trials.
Li J; Sun W
J Chemother; 2018; 30(6-8):323-331. PubMed ID: 30663550
[TBL] [Abstract][Full Text] [Related]
9. Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies.
Cui D; Cao D; Yang Y; Qiu M; Huang Y; Yi C
Mol Biol Rep; 2014 Mar; 41(3):1291-8. PubMed ID: 24390240
[TBL] [Abstract][Full Text] [Related]
10. Diarrhea with epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients: A meta-analysis of randomized controlled trials.
Li J; Gu J
Crit Rev Oncol Hematol; 2019 Feb; 134():31-38. PubMed ID: 30771871
[TBL] [Abstract][Full Text] [Related]
11. Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: a systematic review and meta-analysis.
Funakoshi T; Suzuki M; Tamura K
Cancer Treat Rev; 2014 Dec; 40(10):1221-9. PubMed ID: 25288497
[TBL] [Abstract][Full Text] [Related]
12. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
[TBL] [Abstract][Full Text] [Related]
13. Risk of anti-EGFR monoclonal antibody-related skin rash: an up-to-date meta-analysis of 25 randomized controlled trials.
Qi WX; Sun YJ; Shen Z; Yao Y
J Chemother; 2014 Dec; 26(6):359-68. PubMed ID: 24621163
[TBL] [Abstract][Full Text] [Related]
14. Role of Anti-Epidermal Growth Factor Receptor Therapy Compared with Anti-Vascular Endothelial Growth Factor Therapy for Metastatic Colorectal Cancer: an Update Meta-Analysis of Randomized Clinical Trials.
Wang JX; Wu HL; Zhu M; Zhou R
Pathol Oncol Res; 2020 Jan; 26(1):159-166. PubMed ID: 29383654
[TBL] [Abstract][Full Text] [Related]
15. Risk of hypertension with anti-VEGF monoclonal antibodies in cancer patients: a systematic review and meta-analysis of 105 phase II/III randomized controlled trials.
Yin G; Zhao L
J Chemother; 2022 Jul; 34(4):221-234. PubMed ID: 34229563
[TBL] [Abstract][Full Text] [Related]
16. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.
Dahabreh IJ; Terasawa T; Castaldi PJ; Trikalinos TA
Ann Intern Med; 2011 Jan; 154(1):37-49. PubMed ID: 21200037
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis: the efficacy and safety of monoclonal antibody targeted to epidermal growth factor receptor in the treatment of patients with metastatic colorectal cancer.
Nie F; Shen J; Tong JL; Xu XT; Zhu MM; Ran ZH
J Dig Dis; 2009 Nov; 10(4):247-57. PubMed ID: 19906103
[TBL] [Abstract][Full Text] [Related]
18. Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis.
Zhang S; Chen J; Jiang H; Ma H; Yang B
Eur J Clin Pharmacol; 2012 May; 68(5):561-9. PubMed ID: 22231637
[TBL] [Abstract][Full Text] [Related]
19. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
20. Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody.
Wen F; Tang R; Sang Y; Li M; Hu Q; Du Z; Zhou Y; Zhang P; He X; Li Q
Cancer Sci; 2013 Oct; 104(10):1330-8. PubMed ID: 23822592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
